Mescaline molecule:

Image from PubChem

Mescaline Clinical Trials


Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04227756

Organisation Name: University Hospital, Basel, Switzerland

Overal Status: Recruiting

Start Date: May 19, 2020

Last Update: May 29, 2020

Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary: LSD, psilocybin and mescaline are widely used for recreational and ethnomedical purposes. All three substances are thought to induce prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. However, there are differences in the substances' molecular structures and receptor activation profiles which may induce differential subjective effects. To date, there are no modern studies comparing LSD, psilocybin and mescaline directly within the same clinical study and research subjects using validated psychometric tools. Therefore, the LPM-Study compares the acute effects of LSD, psilocybin, mescaline and placebo in a double-blind, placebo-controlled, 4-period cross-over design with four treatment conditions: 1) 100 μg LSD, 2) 20 mg psilocybin, 3) 300 mg mescaline, and 4) placebo.

Conditions:
  • Healthy


Total execution time in seconds: 0.19230389595032